Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.50 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280411 | 0.86 | MEN1 (0.62) | MEN1KMT2ATXNRD1GSRALDH1A1 | |
| SCHEMBL15688471 | 0.83 | MERTK (0.57) | MEN1KMT2ATXNRD1ALDH1A1MAPT | |
| SCHEMBL20476789 | 0.80 | MEN1 (0.58) | MEN1KMT2ATXNRD1ALDH1A1GSTP1 | |
| SCHEMBL22264083 | 0.80 | MEN1 (0.58) | MEN1KMT2ATXNRD1ALDH1A1GSTP1 | |
| SCHEMBL2272996 | 0.79 | MAPT (0.48) | MEN1KMT2ATXNRD1GSRALDH1A1 | |
| SCHEMBL18508428 | 0.78 | MEN1 (0.51) | MEN1KMT2ATXNRD1GSRGSTP1 | |
| SCHEMBL30498938 | 0.77 | MEN1 (1.00) | MEN1KMT2AALDH1A1GSTP1GSTM2 | |
| SCHEMBL393514 | 0.77 | MEN1 (1.00) | MEN1KMT2AALDH1A1GSTP1GSTM2 | |
| SCHEMBL15227162 | 0.75 | MEN1 (0.63) | MEN1KMT2AALDH1A1GSTP1GSTM2 | |
| SCHEMBL10514409 | 0.75 | TXNRD1 (0.58) | MEN1KMT2ATXNRD1GSRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | MEN1 692/4885KMT2A 265/4885TXNRD1 549/4885 |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | MEN1 692/4885KMT2A 265/4885TXNRD1 549/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | MEN1 692/4885KMT2A 265/4885TXNRD1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.